Drug Allergy
13
4
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Provocation After Nurse-Directed Assessment (PANDA) Study
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping
Teicoplanin Allergy Testing Using Autologous Serum (TATAS)
High Dimensional Analysis of Immune Cells in Pediatric Patients
Inpatient Penicillin Delabeling for Low-Risk Patients
A Training Program of Drug Allergy for Healthcare Professionals
Perioperative Hypersensitivity in Children
Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
Multiple Drug Hypersensitivity Syndrome
Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study